TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
14 hedge funds and large institutions have $9.65M invested in TFF Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
135% more capital invested
Capital invested by funds: $4.11M → $9.65M (+$5.54M)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.4M |
| 2 |
GS
Gagnon Securities
New York
|
+$1.11M |
| 3 |
Renaissance Technologies
New York
|
+$684K |
| 4 |
BlackRock
New York
|
+$154K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$62.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$181K |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$101K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$19K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$16K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$15.9K |
TFFP Hedge Fund Activity: Q2 2020 in Review
14 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q2 2020, worth a combined $9.65M — up 135% from $4.11M a quarter earlier.
Fund positioning in TFFP was balanced in Q2 2020: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $1.4M. The largest seller was Millennium Management, cutting an estimated $181K.
- 14 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $9.65M of TFF Pharmaceuticals, Inc. Common Stock stock for Q2 2020, up 135% quarter-over-quarter.
- 3 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 3 closed out, a net change of 0 holders.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was Nantahala Capital Management, an estimated $1.4M added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was Millennium Management, an estimated $181K sold.
Based on aggregated 13F filings for Q2 2020.